Proteomics Market Size is Expected to Attain US$ 110.13 Billion by 2032

The global proteomics market size was evaluated at US$ 31.55 billion in 2023 and is expected to attain around US$ 110.13 billion by 2032, growing at a CAGR of 14.9% from 2023 to 2032. Combining proteomics with genomics and bioinformatics offers a comprehensive insight into biological systems and their disease mechanisms, driving significant growth in the therapeutics sector.

Proteomics Market Overview

The proteomics market is experiencing rapid growth, driven by its broad applications across various fields. Proteomics, the study of proteomes or sets of proteins within organisms or biological contexts, provides a comprehensive evaluation of protein function and structure, offering insights into the nature of organisms. It enables the analysis of protein expression at different levels, facilitating the assessment of specific cellular responses.

Ask here for sample copy@ https://www.precedenceresearch.com/sample/2306

Qualitative and quantitative proteomic analyses are conducted at post-transcriptional, transcriptomic, and genomic levels, employing various strategies such as post-extraction or metabolic stable-isotope labeling. These techniques find applications in medicine, oncology, food microbiology, agriculture, and more. In medicine, proteomics plays a critical role in early disease diagnosis, prognosis, and monitoring disease progression. Additionally, it is indispensable in drug development, aiding in the identification of target molecules. Proteomics encompasses the characterization of proteomes, including protein expression, structure, functions, interactions, and modifications at any stage, offering comprehensive insights into biological systems.

• In October 2023, Standard BioTools and SomaLogic merged in an all-stock deal, creating a diversified leader in life sciences tools.
• In January 2024, SomaLogic encouraged stockholders to vote “FOR” the pending merger with Standard BioTools to maximize the value of their investment.

Key Insights

• North America region contributed revenue share of 46.2% in 2022.
• By products, the consumables and the reagents segment has captured 71.5% of revenue share in 2022.
• By technology, the spectroscopy segment has generated 47.6% revenue share in 2022.
• By application, the clinical diagnostics segment has garnered revenue share of over 51.8% in 2022.

Immediate delivery is available, Get access of the full report@ https://www.precedenceresearch.com/checkout/2306

Regional Stance

In the North American region, particularly in the United States and Canada, the proteomics market is poised for significant growth. The US Human Proteome Organization (US HUPO) serves as a pivotal hub for education and networking among professionals engaged in proteomics research, particularly focusing on the human proteome and model organisms. Technological advancements in mass spectrometry are driving innovation in proteomic studies, with a notable emphasis on developing automated and high-throughput sample processing workflows to improve reproducibility. These advancements are particularly influential in the identification of biomarkers for early disease detection, predictive modeling, and monitoring therapeutic efficacy in the American market.

Canada, through the Pan-Canadian Proteomics Centre (PCPC), consolidates the research and service capabilities of six leading facilities. These facilities, supported by Genome Canada national service platforms, have a robust track record of providing high-quality proteomics services for over 18 years. Their offerings span a wide range of proteomics technologies, catering to diverse applications in health, agriculture, forestry, energy, and the environment.

The proteomics sector is recognized as a key research area essential for Canada’s economic growth, the country’s expertise in the life sciences. With services accessed by clients nationwide and internationally, the proteomics market in North America is positioned for sustained expansion, driven by technological advancements and growing demand across various industries.

• In January 2024, Biognosys expanded its footprint in the US with a new proteomics CRO facility in Massachusetts.

Report Highlights

By Product

In the proteomics market, the consumables and reagents segment is anticipated to dominate in the upcoming years, driven by increasing demand for products that streamline workflows and enhance efficiency. Automation instrumentation, along with associated consumables, is expected to play a significant role in this segment’s growth. Innovations in proteomics technologies also involve the incorporation of novel affinity reagents for protein binding. For instance, single-stranded DNA aptamers represent a cutting-edge technology recently utilized for large-scale human plasma profiling, demonstrating the continuous evolution and diversification of products within the proteomics market.

Ask here for customization study@ https://www.precedenceresearch.com/customization/2306

Technology Insights

In the proteomics market, the spectroscopy segment held the largest market share, with mass spectrometry emerging as a key technology driving growth and innovation. Mass spectrometry has become instrumental in analyzing biological samples and has evolved into an indispensable tool for proteomics research. The quest to understand the proteome has spurred the development of new technologies that enhance mass spectrometry capabilities, enabling it to address a diverse array of applications. Notably, the introduction of novel mass spectrometers like the Orbitrap, coupled with advancements in dissociation methods such as electron transfer dissociation, has opened up exciting new avenues for proteomic research.

Mass spectrometry applications in proteomics encompass cataloging protein expression, defining protein interactions, and identifying sites of protein modification. These capabilities are crucial for unraveling the complexities of biological systems and elucidating disease mechanisms. The widespread adoption of mass spectrometry underscores its importance in proteomics research and its potential to drive advancements in various fields, including medicine, biotechnology, and pharmaceuticals. As mass spectrometry technology continues to evolve and innovate, it is poised to remain at the forefront of proteomics research, driving market growth and enabling new discoveries in the field.

By Application

In the proteomics market, the segment of clinical diagnostics is poised to maintain its dominance and secure the largest market share in the coming years. Clinical proteomics, specifically, has emerged as a powerful tool for defining specific polypeptide profiles associated with various diseases, such as acute graft-versus-host disease (aGvHD) following allogeneic hematopoietic stem cell transplantation (allo-HSCT). These polypeptide profiles serve as valuable diagnostic markers, enabling accurate disease detection, staging, prognosis, and prediction of therapeutic outcomes. Furthermore, they have the potential to predict disease recurrence or relapse post-treatment, contributing to personalized medicine approaches.

The field of clinical proteomics is characterized by its focus on biomarker discovery for early and precise diagnosis, as well as prognosis improvement. Beyond diagnostics, it also encompasses the identification of new therapeutic targets, drugs, and vaccines, aimed at enhancing therapeutic efficacy and disease prevention. Recent collaborations among proteomics experts, clinicians, biochemists, chemists, bioinformaticians, and statisticians from global institutions underscore the growing momentum in defining the field and establishing robust standards for clinical proteomics. This concerted effort is expected to further drive advancements in clinical diagnostics and therapeutic development, cementing the pivotal role of proteomics in improving healthcare outcomes.

• In June 2023, Biognosys unveiled an innovative workflow for deep and reproducible plasma proteomics, aiming to facilitate breakthroughs in molecular diagnostics and drug development.

Market Dynamics

Driver

Advancements in Biomarker Discovery and Drug Development

Proteomics stands as a revolutionary technique driving significant growth in medicine, particularly in the realms of biomarker discovery and drug development. By analyzing proteins in bodily fluids like urine, serum, breath, and spinal fluid, proteomics enables the identification and monitoring of biomarkers—assessable indicators of normal or abnormal biological states. This capability proves invaluable in clinical settings, where cancer biomarkers play a pivotal role in measuring cancer development and therapeutic response. Furthermore, proteomics provides a comprehensive map of protein interactions associated with disease pathways, facilitating drug development by offering insights into potential targets and mechanisms. Its speed, sensitivity, and ability to provide high proteome coverage position proteomics as a cornerstone technology in advancing healthcare

Restraint

Complexities in Protein Expression and Methodological Limitations

Proteomics faces significant hurdles stemming from the intricate dynamics of protein expression, which can vary widely with environmental factors and cell types. Unlike genomics, proteomics lacks a standardized method akin to polymerase chain reaction, posing a challenge in achieving comparability across studies. Furthermore, protein activities undergo extensive post-translational regulation, adding complexity to proteomic analyses. Additionally, variations in sample types and preparation techniques pose further challenges, impacting the quality of mass spectrometry data and restraining the growth potential of the proteomics market.

Opportunity

Integrating Molecular Insights for Enhanced Diagnostics and Therapeutics

Proteomics has emerged as a cornerstone in molecular sciences, offering crucial insights into protein identity, expression levels, and modifications. In cancer research, proteomics has been pivotal in deciphering mechanisms underlying tumor growth and metastasis, leading to the discovery of clinically relevant biomarkers and therapeutic targets. The establishment of cancer proteome databases, shared globally, underscores the collaborative nature of proteomic advancements. Furthermore, the integration of proteomics with other omics disciplines enables comprehensive molecular profiling, yielding vast datasets ripe for analysis through bioinformatic pipelines. This convergence of technologies presents lucrative opportunities in the proteomics market, driving innovation in diagnostics and therapeutics through data-driven insights.

Recent Developments

• In July 2023, Olink unveiled Olink Explore HT, marking a new era in proteomics.
• In May 2023, Evosep and Cellenion initiated a co-marketing agreement to enhance single-cell proteomics.
• In February 2024, Quantum-Si expanded proteome coverage and increased sequencing output with enhancements to its next-generation protein sequencing platform.
• In October 2023, Thermo Fisher Scientific acquired Olink, a leader in next-generation proteomics.
• In May 2022, CellCarta expanded its proteomics portfolio by acquiring next-generation immuno-MRM assays from Precision Assays.

Key Players in the Proteomics Market

• Thermo Fisher scientific
• Alumna incorporated
• Creative proteomics
• GE healthcare
• Integrated proteomics applications

Market Segmentation

By Product

• Instruments
• Consumables and reagents
  • Immunoassay Reagents
  • Spectroscopy Reagents
  • Chromatography Reagents
  • Protein Microarray Reagents
  • X-Ray Crystallography Reagents
  • Electrophoresis Reagents
  • Protein Fractionation Reagents
  • Services

By Application

• Drug Discovery
  • Target Discovery
  • Lead Identification
  • Lead Optimization
  • Preclinical Studies
• Clinical Diagnostics
  • Cancer
  • Immune Diseases
  • Infectious Diseases
  • Neurological Disorders
  • Diabetes
  • Cardiovascular Diseases
  • Other Clinical Diagnostic Applications
• Others

By Technology

• Spectroscopy
  • NMR Spectroscopy
  • CD Spectroscopy
  • Mass Spectroscopy
• Microarray instruments
• Chromatography
  • HPLC
  • Ion Chromatography
  • Affinity Chromatography
  • Supercritical Fluid Chromatography
• X-ray crystallography
• Protein Microarrays
  • Biochips
    • Lab-on-Chips
    • Protein Chips
  • Microarray Instruments
    • Integrated Systems
    • Microarray Scanners
    • Arrayers
• Electrophoresis
  • Gel Electrophoresis
  • Capillary Electrophoresis
• Protein fractionation system
• Surface plasma resonance systems

By Software & Service

• Core Proteomics Services
  • Protein Identification Services
  • Protein Characterization Services
  • Quantitative Proteomic Services
  • Protein Purification Services
  • Protein Sequencing Services
  • Custom Assay Services
• Bioinformatics Software & Services
  • Bioinformatics Software
  • Bioinformatics Tools
  • Bioinformatics Databases

By End User

• Hospitals
• Clinical Laboratories
• Pharmaceutical Companies
• Academic Research Laboratories
• Others

By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

Immediate delivery is available, Get access of the full report@ https://www.precedenceresearch.com/checkout/2306

OR

Call: USA: +1 650 460 3308 | IND: +91 87933 22019 | Europe: +44 2080772818

Email: sales@precedenceresearch.com